Zheng Huang

发表

Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding affinity.

R. Young, J. Mancini, M. Turner, 2003, Journal of medicinal chemistry.

Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor.

J. Mancini, R. Friesen, D. Guay, 2008, Bioorganic & medicinal chemistry letters.

Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.

Chun Xing Li, R. Young, S. Charleson, 2005, Bioorganic & medicinal chemistry letters.

Enantiomer discrimination illustrated by the high resolution crystal structures of type 4 phosphodiesterase.

H. Ke, Huanchen Wang, Q. Huai, 2006, Journal of medicinal chemistry.

Rapid measurement of deuterium-labeled long-chain fatty acids in plasma by HPLC-ESI-MS Published, JLR Papers in Press, October 4, 2006.

K. Bateman, S. Gagné, C. Li, 2007, Journal of Lipid Research.

Nicotinic acids: liver-targeted SCD inhibitors with preclinical anti-diabetic efficacy.

R. Oballa, R. Gordon, J. Guay, 2011, Bioorganic & medicinal chemistry letters.

The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors.

R. Young, D. Nicholson, Y. Girard, 2010, Bioorganic & medicinal chemistry letters.

Preferential inhibition of human phosphodiesterase 4 by ibudilast.

Y. Natsumeda, M. Salem, Zheng Huang, 2006, Life sciences.

Discovery of L-791,943: a potent, selective, non emetic and orally active phosphodiesterase-4 inhibitor.

R. Young, C. Brideau, D. Guay, 2002, Bioorganic & medicinal chemistry letters.

Phosphodiesterase 4 inhibitors for the treatment of asthma and COPD.

J. Mancini, Zheng Huang, 2006, Current medicinal chemistry.

Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.

R. Young, J. Mancini, D. Nicholson, 2009, Bioorganic & medicinal chemistry letters.

Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.

R. Young, J. Mancini, H. Perrier, 2008, Bioorganic & medicinal chemistry letters.

Conversion of systemically-distributed triazole-based stearoyl-CoA desaturase (SCD) uHTS hits into liver-targeted SCD inhibitors.

J. Falgueyret, R. Oballa, J. Guay, 2011, Bioorganic & medicinal chemistry letters.

Thiazole analog as stearoyl-CoA desaturase 1 inhibitor.

J. Guay, C. Li, Yeeman K. Ramtohul, 2009, Bioorganic & medicinal chemistry letters.

In vitro PKA phosphorylation‐mediated human PDE4A4 activation

M. Gresser, Zheng Huang, F. Laliberté, 2002, FEBS letters.

Dynamic Activation of Cystic Fibrosis Transmembrane Conductance Regulator by Type 3 and Type 4D Phosphodiesterase Inhibitors

M. Tota, A. Veilleux, R. Friesen, 2005, Journal of Pharmacology and Experimental Therapeutics.

SAR and optimization of thiazole analogs as potent stearoyl-CoA desaturase inhibitors.

R. Oballa, J. Guay, Sébastien Guiral, 2010, Bioorganic & medicinal chemistry letters.

Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438).

J. Falgueyret, R. Oballa, J. Guay, 2010, Bioorganic & medicinal chemistry letters.

Plasma-based approach to measure target engagement for liver-targeting stearoyl-CoA desaturase 1 inhibitors

R. Oballa, K. Bateman, C. Li, 2011, Journal of Lipid Research.

2-Aryl benzimidazoles: human SCD1-specific stearoyl coenzyme-A desaturase inhibitors.

J. Falgueyret, R. Oballa, P. Tawa, 2010, Bioorganic & medicinal chemistry letters.

A Multiplexed Cell Assay in HepG2 Cells for the Identification of Delta-5, Delta-6, and Delta-9 Desaturase and Elongase Inhibitors

J. Guay, S. Gagné, A. Styhler, 2010, Journal of biomolecular screening.

Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis.

S. Jin, M. Conti, D. Macdonald, 2002, The Journal of clinical investigation.

Naphthalenebis[α,α-difluoromethylenephosphonates] as potent inhibitors of protein tyrosine phosphatases

Scott D. Taylor, C. Ramachandran, Qingping Wang, 1998 .

Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia.

David A. Powell, Lei Zhang, R. Oballa, 2011, Journal of medicinal chemistry.

Stearoyl-CoA desaturase inhibition blocks formation of hepatitis C virus-induced specialized membranes

Andrew Ridsdale, John Paul Pezacki, Rodney K. Lyn, 2014, Scientific Reports.

Nitrogen-bridged substituted 8-arylquinolines as potent PDE IV inhibitors.

S. Charleson, J. Mancini, H. Perrier, 2006, Bioorganic & medicinal chemistry letters.

Discovery of potent and liver-targeted stearoyl-CoA desaturase (SCD) inhibitors in a bispyrrolidine series.

R. Oballa, S. Léger, Sébastien Guiral, 2012, Bioorganic & medicinal chemistry letters.

Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.

R. Young, J. Mancini, R. Friesen, 2010, Bioorganic & medicinal chemistry letters.

Conformational difference between PDE4 apoenzyme and holoenzyme.

A. Govindarajan, Yongxin Han, M. Gresser, 2000, Biochemistry.

Methyl arachidonyl fluorophosphonate: a potent irreversible inhibitor of anandamide amidase.

D. Deutsch, G. Prestwich, A. Howlett, 1997, Biochemical pharmacology.

Bicyclic heteroaryl inhibitors of stearoyl-CoA desaturase: from systemic to liver-targeting inhibitors.

Lei Zhang, Serge Leger, Jean-Philippe Leclerc, 2011, Bioorganic & medicinal chemistry letters.

Slow- and tight-binding inhibitors of the 85-kDa human phospholipase A2.

M. Gelb, H. Perrier, F. Ghomashchi, 1993, Biochemistry.

Biological activity and preclinical efficacy of azetidinyl pyridazines as potent systemically-distributed stearoyl-CoA desaturase inhibitors.

R. Oballa, R. Gordon, J. Guay, 2011, Bioorganic & medicinal chemistry letters.

A Multiplexed Cell Assay in HepG2 Cells for the Identification of Delta-5, Delta-6, and Delta-9 Desaturase and Elongase Inhibitors

J. Guay, S. Gagné, A. Styhler, 2010, Journal of biomolecular screening.

Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.

R. Young, J. Mancini, R. Friesen, 2010, Bioorganic & medicinal chemistry letters.

Solid phase parallel synthesis of highly substituted thiophene derivatives and identification of novel phosphodiesterase-4 (PDE-4) inhibitors

C. Bayly, R. Young, Yongxin Han, 1999 .